Sandoz Establishes New Biosimilar Unit, Appoints Armin Metzger

Sandoz Group AG has announced the creation of a global biosimilar development, manufacturing, and supply unit. This strategic move aims to harness the anticipated opportunities arising from upcoming expirations of medical exclusivity worth over USD 650 billion in the next decade. Armin Metzger will lead this new unit, joining the Sandoz Executive Committee on April 1, 2026.

This initiative strengthens Sandoz's position as a leader in biosimilars and generics, focusing on growth in biosimilars while bolstering generics. The consolidation under Metzger's leadership is expected to streamline decision-making and foster integration across all operational facets of biosimilars.

Other organizational changes include Claire D’Abreu-Hayling as President of Generics Development, and Glenn Gerecke as President of Generics Manufacturing & Supply. These changes aim to enhance focus on the core high-volume, lower-cost generics business.